Urological Research Foundation's home page
About the Urological Research Foundation
Prostate Cancer Questions & Answers
Quest Newsletter Articles
Media articles and interviews with Dr. Catalona
Books published by other authors
Dr. Catalona's journal articles from various publications
Dr. Catalona's genetic research for prostate cancer
Donate to the URF for prostate cancer research
View the New Patient Packet sent by Dr. Catalona
Links to other helpful prostate cancer websites
Contact the Urological Research Foundation
Dr. Catalona's Library Articles


FREQUENT AND EARLY LOSS OF THE EGR1 COREPRESSOR NAB2 IN HUMAN PROSTATE CARCINOMA.

Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalona WJ, Milbrandt J.

The transcription factor EGR1 is frequently overexpressed in human prostate cancer and regulates the expression of several genes important for tumor progression. In addition, mice lacking the Egr1 gene show a defect in prostate tumorigenesis. NAB2 is a novel corepressor molecule that modulates EGR1 activity and is induced by the same stimuli that induce EGR1. The human NAB2 gene has been localized to 12q13.3-14.1, within a chromosomal region that is thought to harbor a prostate tumor suppressor. We have examined the expression of NAB2 in human prostate carcinoma specimens. We show here that NAB2 protein expression is lost in a majority of primary prostate carcinoma specimens, including many samples that have high EGR1 levels. This loss occurs early in the tumorigenic process and is sustained, as it is seen in precursor prostatic intraepithelial neoplasia lesions as well as in metastases. Furthermore, loss of NAB2 did not correlate with the tumor grade or stage. Our findings suggest that high levels of EGR1 coupled with low levels of NAB2 can result in high, unrestrained EGR1 transcriptional activity in human prostate cancers. Copyright 2001 by W.B. Saunders Company

Institution: Department of Pathology and Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA.


Human Pathology. 32(9):935-9, 2001 Sep.


Home    |    About the URF   |    Q & A - Prostate Cancer   |    Quest Articles
Journal Articles   |    National Media   |    Suggested Reading   |    Genetic Research
Donations   |    New Patient Packet   |    Post-Op Advice   |    Helpful Links   |    Contact Us